Dr Nazir Ahmed, Dr. Seemab Asghar, Dr Tehreem Shazadi
Aim: In Covid 2019 (Coronavirus) patients routinely undergo comorbidities but the clinical ramifications are not yet highly documented. We hope to portray the pervasiveness and clinical implications of comorbidities in patients with COVID-19. Methods: Our current research was conducted at Services Hospital, Lahore from March 2020 to September 2020. This is a multi-focused study, including patients granted from March 2020 to September 2020. At least one of the accompanying, rescue unit or mechanic ventilation criteria, or again, was characterized by the composite endpoint. Results: In total, 52 affirmed COVID-19 tertiary emergency care clinics have been accepted into 477 consecutive instances (mean age 45 [34-54.6] years old and 54.2 percent male). Comorbidity in 101 patients was present (21.4%), including hypertension (16.1%), mellitus diabetes (8.9%) and coronary supply pathway disorder (2.6%), continued pneumonic obstruction (2.4%) and stroke (2.8%) respectively. The composite endpoint happened in 65 (14.9%) patients. The step-by - step multivariate reappointment analysis found more defined age (OR 1.39, 95 % CI 2.06–1.86), hypertension precursor (OR 3.83, 96% CI 1.0,8.18), neutrophil tests (OR 1.33, 95 % CI 1.14–1,56) and level of lactate dehydrogenase (OR 1,03, 99% CI 1.00–1,01) to be linked autonomously. The composite endpoint (p<.002) and each individual endpoint, including ICU confirmation (p<.002), the mechanical ventilation (p<.002), and disappearing (p1⁄4.012), were more visible for hypertension, contrast, and control patients. Neither therapy predicted the combined endpoint during the step-by - step repetition analysis of antihypertensive medications. Conclusion: Hypertension is a typical comorbidity in patients with COVID-19 and related with unfriendly results. Keywords: Risk, Adverse Events, Hypertension, Coronavirus Disease 2019.